326 related articles for article (PubMed ID: 21442348)
1. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Meyers MO; Klauber-Demore N; Ollila DW; Amos KD; Moore DT; Drobish AA; Burrows EM; Dees EC; Carey LA
Ann Surg Oncol; 2011 Oct; 18(10):2851-7. PubMed ID: 21442348
[TBL] [Abstract][Full Text] [Related]
2. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
5. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.
Lowery AJ; Kell MR; Glynn RW; Kerin MJ; Sweeney KJ
Breast Cancer Res Treat; 2012 Jun; 133(3):831-41. PubMed ID: 22147079
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
7. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
8. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.
Wang J; Luo J; Jin K; Wang X; Yang Z; Ma J; Mei X; Wang X; Zhou Z; Yu X; Chen X; Guo X
Cancer Med; 2020 Apr; 9(7):2427-2434. PubMed ID: 32048817
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
11. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype.
McGuire A; Lowery AJ; Kell MR; Kerin MJ; Sweeney KJ
Ann Surg Oncol; 2017 Oct; 24(11):3124-3132. PubMed ID: 28755141
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
14. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
16. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
17. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
[TBL] [Abstract][Full Text] [Related]
18. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
Yamazaki N; Wada N; Yamauchi C; Yoneyama K
Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
[TBL] [Abstract][Full Text] [Related]
19. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]